Dr. Alan D. Dauer, MD

Dr. Dauer practices at Cedars-Sinai Medical Center in West Hollywood, California.

Dr. Dauer's NPI, 1164493508, was assigned on February 1, 2006. Dr. Dauer graduated from New York Medical College in 1962. Dr. Dauer holds California license WG8836F.

Dr. Dauer's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, West Hollywood, CA 90048 in Los Angeles County. The practice phone is (323) 866-8600.

Dr. Dauer's primary practice is Cedars-Sinai Medical Center in West Hollywood, California. The medical group on file is Tower Nephrology Medical Group. Dmand AI also links Dr. Dauer to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dauer practices. Vendor and product names are available with a free account.

Nephrology is Dr. Dauer's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Dauer is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Dauer's licenses on file in 2 states: California and New York.

Dmand AI lists acute sinusitis, chronic diabetes, chronic hypertension, depression, diabetic emergency, ear infection, fluid and electrolyte imbalances and high cholesterol among the conditions Dr. Dauer treats.

CMS data shows 74 Medicare services from Dr. Dauer across 3 procedure codes in 2024, for 39 Medicare patients. Medicare paid $6,447 for them. Every service was in an office.

CMS counts 39 Medicare patients who saw Dr. Dauer in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 28% are also on Medicaid. Their average risk score is 1.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dauer's median patient age at 72, with 20% women.

In 2024, Dr. Dauer wrote 345 Medicare Part D claims for 43 patients. 84% of them were for generic drugs. CMS names the drug for 115 of them, across 7 drugs with 11 or more claims each, at $12,102 in total drug cost. In 2023, CMS named 387 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Dauer for performance year 2024, reported as part of a group.

CMS Open Payments shows 616 general payments to Dr. Dauer from 51 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 99% of the total. Amgen Inc. paid the most, $2,156.

Dmand AI lists 1 award for Dr. Dauer, most recently CMS Stage 1 EHR in 2013.

Dr. Dauer graduated from New York Medical College in 1962.

Dr. Dauer is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.